618460-38-1

Basic information

• Product Name: D-clovamide methyl ester
• Synonyms: D-clovamide methyl ester
• CAS NO: 618460-38-1
• Molecular Weight: 373.362
• Mol File: 618460-38-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: D-clovamide methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: D-clovamide methyl ester(618460-38-1)
• EPA Substance Registry System: D-clovamide methyl ester(618460-38-1)

Safety Data

• Hazardous Substances Data: 618460-38-1(Hazardous Substances Data)

Upstream product

• 331-39-5 caffeic acid 
• 71855-43-1 (R)-(3,4-dihydroxyphenyl)alanine methyl ester 
• 67-56-1 methanol 
• 5796-17-8 D-Dopa 
• 331-39-5 caffeic acid 
• 889133-43-1 methyl (R)-2-amino-3-(3,4-dihydroxyphenyl)propanoate hydrochloride salt 
• 626201-03-4 (R)-3-(3,4-Dihydroxy-phenyl)-2-[(E)-3-(3,4-dimethoxy-phenyl)-acryloylamino]-propionic acid methyl ester 

Downstream Products

• 618460-39-2 D-clovamide 
• 626201-07-8 (R)-3-(3,4-Dihydroxy-phenyl)-2-[(E)-3-(4-hydroxy-3-methoxy-phenyl)-allylamino]-propionic acid methyl ester 
• 618460-97-2 3-(3,4-dihydroxy-phenyl)-(R)-2-[3-trans-(3,4-dihydroxy-phenyl)-thioacryloylamino]-propionic acid methyl ester tetra(t-butyl dimethylsilyl)ether 
• 618460-96-1 N-(3',4'-dihydroxy-trans-cinamoyl)-3-(3,4-dihydroxylphenyl)-D-alanine methyl ester tetra (t-butyldimethylsilyl)ether 

Relevant articles and documents

Structure-activity relationship of clovamide and its related compounds for the inhibition of amyloid β aggregation

Alzheimer's disease (AD), a neurodegenerative disorder, is characterized by aggregation of amyloid β-protein (Aβ). Aβ aggregates through β-sheet formation and induces cytotoxicity against neuronal cells. Inhibition of Aβ aggregation by naturally occurring compounds is thus a promising strategy for the treatment of AD. We have already reported that caffeoylquinic acids and phenylethanoid glycosides, which possess two or more catechol moieties, strongly inhibited Aβ aggregation. Clovamide (1) containing two catechol moieties, isolated from cacao beans (Theobroma cacao L.), is believed to exhibit preventive effects on Aβ aggregation. To investigate the structure-activity relationship of clovamide (1) for the inhibition of Aβ aggregation, we synthesized 1 and related compounds 2–11 through reaction between L-DOPA, D-DOPA, L-tyrosine, or L-phenylalanine and caffeic acid, p-coumaric acid, or cinnamic acid, and compounds 12 and 13 were derived from 1. Among tested compounds 1–13, those containing one or two catechol moieties exhibited potent anti-aggregation activity, whereas the non-catechol-type related compounds showed little or no activity. This suggests that at least one catechol moiety is essential for inhibition of Aβ42 aggregation, and this activity increases depending on the number of catechol moieties. Consequently, clovamide (1) and its related compounds may be a promising therapeutic option for inhibiting Aβ-mediated pathology in AD.

Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition

The present invention relates to derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition, more particularly the compounds of the present invention specifically inhibit the activation of T lymphocyte by src homology region 2(SH2) domain of T lymphocyte (lck), so that they can be used for the treatment, prevention and/or diagnosis of graft rejection, autoimmune diseases, inflammatory diseases, etc.